Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has initiated the pivotal Phase 3 RASolute 305 trial evaluating zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic ductal adenocarcinoma. The trial targets a high-prevalence mutation found in roughly 40% of pancreatic cancer patients, a disease with a five-year survival rate of only 3%.
Key figures
- Drug Name
- zoldonrasib
- Phase Of Trial
- Phase 3
- G12d prevalence pdac
- 40%
- Ras mutation prevalence pdac
- >90%
- G12d prevalence all ras cancers
- 29%
- Annual us pancreatic cancer deaths
- 50000
- Annual us pancreatic cancer diagnoses
- 60000
- Estimated annual us g12d new patients
- 61000
- Five year survival rate metastatic pdac
- 3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.